22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › INOVIO PHARMACEUTICALS INC. › 2024-2025

INOVIO PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed May 22, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Ballot items
  • 147Asset managers, any item
  • 983Fund votes
  • May 20, 2025Meeting date

Results at a glance

Meeting of May 20, 2025: 11 items on INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed May 22, 2025: 11 passed (calculated).

Dissent

Notable dissent: 1 director (19.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 7.0%, as of September 30, 2026)

Explore INOVIO PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by INOVIO PHARMACEUTICALS INC.

These tallies are INOVIO PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INOVIO PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 20, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Simon X. Benito 7,316,456---- 1,747,26810,956,881 81%Passed (calculated)—
Elect Director: Roger D. Dansey, M.D. 8,172,640---- 891,08410,956,881 90%Passed (calculated)—
Elect Director: Ann C. Miller, M.D. 8,360,784---- 702,94010,956,881 92%Passed (calculated)—
Elect Director: Jacqueline E. Shea, Ph.D. 8,283,381---- 780,34310,956,881 91%Passed (calculated)—
Elect Director: Jay P. Shepard 8,250,576---- 813,14810,956,881 91%Passed (calculated)—
Elect Director: David B. Weiner, Ph.D. 8,378,177---- 685,54710,956,881 92%Passed (calculated)—
Elect Director: Wendy L. Yarno 8,194,523---- 869,20110,956,881 90%Passed (calculated)—
Elect Director: Lota S. Zoth 8,421,250---- 642,47410,956,881 93%Passed (calculated)—
2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 19,263,636600,195156,774 --0 97%Passed (calculated)—
3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement 7,853,0031,058,436152,285 --10,956,881 88%Passed (calculated)—
4. The approval of the amendment and restatement of the Company's 2023 Omnibus Incentive Plan as described in the Proxy Statement 7,764,4691,165,985133,270 --10,956,881 87%Passed (calculated)—

Source: INOVIO PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 22, 2025 — read the filing on EDGAR.

How asset managers voted at the INOVIO PHARMACEUTICALS INC. 2024-2025 meeting

147 asset managers disclosed a vote on at least one INOVIO PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Ann C. Miller, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 8,360,784WITHHELD: 702,940

Prior year: 85.0% for (May 21, 2024 meeting) ▲ 7.2 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 8,360,784 for, 702,940 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,171,298 for.

FOR
FOR: 2,171,298
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: David B. Weiner, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 8,378,177WITHHELD: 685,547

Prior year: 94.1% for (May 21, 2024 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 8,378,177 for, 685,547 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,171,298 for.

FOR
FOR: 2,171,298
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: Jacqueline E. Shea, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 8,283,381WITHHELD: 780,343

Prior year: 93.9% for (May 21, 2024 meeting) ▼ 2.5 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 8,283,381 for, 780,343 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,171,298 for.

FOR
FOR: 2,171,298
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: Jay P. Shepard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 8,250,576WITHHELD: 813,148

Prior year: 92.6% for (May 21, 2024 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay P. Shepard”): 8,250,576 for, 813,148 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,168,810 for, 2,488 withheld.

FOR
FOR: 2,168,810WITHHOLD: 2,488
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert00 02,488Withhold
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: Lota S. Zoth

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 8,421,250WITHHELD: 642,474

Prior year: 84.9% for (May 21, 2024 meeting) ▲ 8.0 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lota S. Zoth”): 8,421,250 for, 642,474 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,160,739 for, 5,726 withheld, 4,833 abstained.

FOR
FOR: 2,160,739ABSTAIN: 4,833WITHHOLD: 5,726
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional00 05,726Withhold
Jackson National00 4,8330Abstain
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: Roger D. Dansey, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 8,172,640WITHHELD: 891,084

Prior year: 92.4% for (May 21, 2024 meeting) ▼ 2.2 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 8,172,640 for, 891,084 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,168,661 for, 2,637 withheld.

FOR
FOR: 2,168,661WITHHOLD: 2,637
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert00 02,488Withhold
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: Simon X. Benito

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 7,316,456WITHHELD: 1,747,268

Prior year: 92.0% for (May 21, 2024 meeting) ▼ 11.3 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Simon X. Benito”): 7,316,456 for, 1,747,268 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,046,529 for, 119,936 withheld, 4,833 abstained.

FOR
FOR: 2,046,529ABSTAIN: 4,833WITHHOLD: 119,936
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust00 076,077Withhold
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial00 020,100Withhold
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street00 010,677Withhold
ProShares7,8240 00For
Dimensional00 05,726Withhold
Jackson National00 4,8330Abstain
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya00 02,698Withhold
Calvert00 02,488Withhold
Brinker Capital Destinations Trust00 01,121Withhold
PENN SERIES FUNDS INC00 0900Withhold

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Elect Director: Wendy L. Yarno

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 8,194,523WITHHELD: 869,201

Prior year: 76.5% for (May 21, 2024 meeting) ▲ 13.9 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 8,194,523 for, 869,201 withheld, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,158,251 for, 8,214 withheld, 4,833 abstained.

FOR
FOR: 2,158,251ABSTAIN: 4,833WITHHOLD: 8,214
Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2026 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional00 05,726Withhold
Jackson National00 4,8330Abstain
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert00 02,488Withhold
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

The approval of the amendment and restatement of the Company's 2023 Omnibus Incentive Plan as described in the Proxy…

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 7,764,469AGAINST: 1,165,985
Details: description as filed, official tally, votes by 33 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR 2023 OMNIBUS INCENTIVE PLAN.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“4. The approval of the amendment and restatement of the Company's 2023 Omnibus Incentive Plan as described in the Proxy Statement”): 7,764,469 for, 1,165,985 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 33 asset managers below reported 2,128,290 for, 43,142 against.

FOR
FOR: 2,128,290AGAINST: 43,142
Largest asset managers voting on “TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR 2023 OMNIBUS INCENTIVE PLAN.” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century043,142 00Against
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 33 asset managers. All 33 are in the interactive database (link above).

The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 7,853,003AGAINST: 1,058,436
Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 7,853,003 for, 1,058,436 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 30 asset managers voting on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive offi” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional05,726 00Against
Jackson National04,833 00Against
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Fund voting reports, all 30 managers: 2,160,739 for, 10,559 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 129 asset managers voting on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive offi” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Deep Track Capital, LP1,676,2540 00For
Stonepine Capital Management, LLC701,1230 00For
State Street474,5520 00For
GEODE CAPITAL MANAGEMENT, LLC366,9580 00For
BlackRock324,9700 00For
Northern Trust217,7770 00For
Nuveen103,2970 00For
Fidelity100,8300 00For
Charles Schwab98,4950 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC87,2400 00For
CIBC Private Wealth Group LLC77,0000 00For
GMT CAPITAL CORP68,7490 00For
Two Sigma63,9480 00For
MELLON INVESTMENTS Corp61,6710 00For
UBS43,445201 00For
American Century43,1420 00For
Vanguard37,8290 00For
Citadel28,0140 00For
Freedom Investment Management, Inc.19,2300 00For
Dimensional018,743 00Against
REGENTS OF THE UNIVERSITY OF CALIFORNIA013,400 00Against
Invesco10,7610 00For
WASHINGTON STATE INVESTMENT BOARD10,5770 00For
STIFEL NICOLAUS & CO INC \MO\10,5510 00For
T. Rowe Price10,1770 00For

Institutional-manager reports, all 129 managers: 4,739,214 for, 44,316 against. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

97% Majority: yes · of votes cast

FOR 97%
FOR: 19,263,636AGAINST: 600,195

Prior year: 96.2% for (May 21, 2024 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 30 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 19,263,636 for, 600,195 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 30 asset managers below reported 2,171,149 for, 149 against.

FOR
FOR: 2,171,149AGAINST: 149
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at INOVIO PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard783,4930 00For
BlackRock588,6340 00For
Fidelity321,7350 00For
Charles Schwab98,4930 00For
Northern Trust76,0770 00For
TIAA46,4910 00For
American Century43,1420 00For
QUANTITATIVE MASTER SERIES LLC37,3060 00For
Equitable24,2310 00For
Global X20,7570 00For
Bridge Builder Trust20,3160 00For
Lincoln Financial20,1000 00For
AIG/SunAmerica17,7080 00For
Pacific Life15,2260 00For
Goldman Sachs13,2150 00For
State Street10,6770 00For
ProShares7,8240 00For
Dimensional5,7260 00For
Jackson National4,8330 00For
Nationwide3,4480 00For
T. Rowe Price3,0300 00For
Voya2,6980 00For
Calvert2,4880 00For
Brinker Capital Destinations Trust1,1210 00For
PENN SERIES FUNDS INC9000 00For

Showing the 25 largest of 30 asset managers. All 30 are in the interactive database (link above).

Largest INOVIO PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 36,674,436 shares outstanding at the time of that meeting.

Fund voting reports: top INOVIO PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 2.14%
2BlackRock 1.61%
3Fidelity 0.88%
4Charles Schwab 0.27%
5Northern Trust 0.21%
6TIAA 0.13%
7American Century 0.12%
8QUANTITATIVE MASTER SERIES LLC 0.10%
9Equitable 0.07%
10Global X 0.06%
Institutional-manager reports: top INOVIO PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named…”, 2024-2025
#Asset manager % of shares outstanding
1Deep Track Capital, LP 4.57%
2Stonepine Capital Management, LLC 1.91%
3State Street 1.29%
4GEODE CAPITAL MANAGEMENT, LLC 1.00%
5BlackRock 0.89%
6Northern Trust 0.59%
7Nuveen 0.28%
8Fidelity 0.27%
9Charles Schwab 0.27%
10PARAMETRIC PORTFOLIO ASSOCIATES LLC 0.24%

Reported INOVIO PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

INOVIO PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
JANUS HENDERSON GROUP PLC6,666,295 18.18%Schedule 13G, filed December 8, 2025
HIGHBRIDGE CAPITAL MANAGEMENT LLC6,190,475 16.88%Schedule 13G, filed May 15, 2026
Adage Capital Management, L.P.4,233,529 11.54%Schedule 13G, filed May 13, 2026
Alyeska Investment Group, L.P.4,000,000 10.91%Schedule 13G, filed February 17, 2026
Highbridge Capital Management, LLC3,633,333 9.91%Schedule 13G, filed February 10, 2025
BlackRock2,318,480 6.32%Form 13F, quarter ended March 31, 2025
Vanguard Group2,028,960 5.53%Form 13F, quarter ended March 31, 2025
Stonepine Capital Management, LLC1,434,997 3.91%Schedule 13G, filed May 14, 2025
Geode Capital846,803 2.31%Form 13F, quarter ended March 31, 2025
State Street514,148 1.40%Form 13F, quarter ended March 31, 2025

Percentages above are of 36,674,436 shares outstanding, as reported by INOVIO PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At INOVIO PHARMACEUTICALS INC.'s shareholder meeting held May 20, 2025, in the 2024-2025 proxy season, 147 asset managers reported votes on at least one of its 11 ballot items in their SEC Form N-PX filings, covering 983 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: INOVIO PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INOVIO PHARMACEUTICALS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

INOVIO PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “INOVIO PHARMACEUTICALS (INO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/inovio-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.